Miller KD - Search Results

1

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.

Gökmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, Shen C, Bruckheimer E, Kinch MS, Miller KD. Gökmen-Polar Y, et al. Among authors: miller kd. Breast Cancer Res Treat. 2011 Jun;127(2):375-84. doi: 10.1007/s10549-010-1004-y. Epub 2010 Jul 3. Breast Cancer Res Treat. 2011. PMID: 20602165

2

The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.

Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr. Sweeney CJ, et al. Among authors: miller kd. Cancer Res. 2001 Apr 15;61(8):3369-72. Cancer Res. 2001. PMID: 11309294

3

Issues and challenges for antiangiogenic therapies.

Miller KD. Miller KD. Breast Cancer Res Treat. 2002 Oct;75 Suppl 1:S45-50; discussion S57-8. doi: 10.1023/a:1020317917759. Breast Cancer Res Treat. 2002. PMID: 12353823 Review.

4

E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer.

Miller KD. Miller KD. Clin Breast Cancer. 2003 Feb;3(6):421-2. doi: 10.3816/CBC.2003.n.007. Clin Breast Cancer. 2003. PMID: 12636887 No abstract available.

5

EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.

Lu M, Miller KD, Gokmen-Polar Y, Jeng MH, Kinch MS. Lu M, et al. Among authors: miller kd. Cancer Res. 2003 Jun 15;63(12):3425-9. Cancer Res. 2003. PMID: 12810680

6

Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer.

Kumar S, Kishimoto H, Chua HL, Badve S, Miller KD, Bigsby RM, Nakshatri H. Kumar S, et al. Among authors: miller kd. Am J Pathol. 2003 Dec;163(6):2531-41. doi: 10.1016/s0002-9440(10)63608-5. Am J Pathol. 2003. PMID: 14633625 Free PMC article.

7

A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer.

Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, Sparano JA, Wolff AC, Cobleigh MA, Galbraith S, Sledge GW. Miller KD, et al. Clin Cancer Res. 2004 Mar 15;10(6):1971-5. doi: 10.1158/1078-0432.ccr-03-0968. Clin Cancer Res. 2004. PMID: 15041714 Clinical Trial.

8

Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?

Miller KD. Miller KD. Breast Cancer Res. 2004;6(3):128-32. doi: 10.1186/bcr782. Epub 2004 Mar 18. Breast Cancer Res. 2004. PMID: 15084233 Free PMC article. Review.

9

The role of ErbB inhibitors in trastuzumab resistance.

Miller KD. Miller KD. Oncologist. 2004;9 Suppl 3:16-9. doi: 10.1634/theoncologist.9-suppl_3-16. Oncologist. 2004. PMID: 15163843 Free article. Review.

10

Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory.

Miller KD, Soule SE, Calley C, Emerson RE, Hutchins GD, Kopecky K, Badve S, Storniolo A, Goulet R, Sledge GW Jr. Miller KD, et al. Breast Cancer Res Treat. 2005 Jan;89(2):187-97. doi: 10.1007/s10549-004-2044-y. Breast Cancer Res Treat. 2005. PMID: 15692762 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

525 results

Search Page

Filters